Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).

REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada.

Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates

Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala's shareholders and the satisfaction of customary closing conditions

Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Wilmington, Delaware--(Newsfile Corp. - October 21, 2022) - Rigrodsky Law, P.A. is investigating Ayala Pharmaceuticals, Inc. ("Ayala") (NASDAQ: AYLA) regarding possible breaches of fiduciary duties and other violations of law related to Ayala's agreement to merge with Advaxis, Inc. ("Advaxis"). Under the terms of the agreement, Ayala shareholders will receive 0.1874 shares of Advaxis common stock for each share of Ayala common stock.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-ayala-pharmaceuticals-inc.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ayala Pharmaceuticals, Inc. Merger

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) and Advaxis, Inc. is fair to Ayala shareholders.

AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders

Merger brings U.S. management and presence, cash to develop compelling late-stage asset

Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that it will host a key opinion leader (KOL) webinar on unmet medical needs and evolving treatment landscape of desmoid tumors on Thursday, October 6, 2022, at 8:00 am ET.

Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors

REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AL102 for the treatment of progressing desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor.

Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors

Ayala Pharmaceuticals, Inc. (AYLA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ayala Pharmaceuticals, Inc. (AYLA) Upgraded to Buy: Here's Why

Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study

Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress

Blue Water Vaccines

E-Home Household Service Holdings Ltd

Ameri Holdings

Koss

Stronghold Digital Mining

SIGA Technologies

The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic about.

7 Short-Squeeze Stocks to Put on Your Must-Watch List

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 20.59% and 95.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Misses Revenue Estimates

Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development

Ayala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Hour Loop

Performance Shipping

Hot low float penny stocks to watch. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 To Watch After LTRPB Stock Jumped Over 372%

Despite a lack of new clinical news concerning Ayala Pharmaceuticals, the short-squeeze mob seems to have taken control of AYLA stock. The post Why Is Ayala Pharmaceuticals (AYLA) Stock Up 100%+ Today?

Why Is Ayala Pharmaceuticals (AYLA) Stock Up 100%+ Today?

- Tumor shrink ing observed in substantially all patients who were evaluable at 16 weeks -

Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors

REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will participate in a “Fireside Chat” presentation at the Jefferies Healthcare Conference, to take place June 8-10, 2022, in New York, NY. The company will also be available for one-on-one meetings with institutional investors at the conference.

Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates

Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 Interim data from Part A of RINGSIDE study of AL102 expected mid-2022

Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present a poster featuring data on AL101 in adenoid cystic carcinoma (ACC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place June 3-7, 2022 in Chicago, Illinois.

Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates

- Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 – - Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 –

Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the 32nd Annual Oppenheimer Healthcare Conference, taking place on March 15-17, 2022. The company will also participate in one-on-one investor meetings at the conference.

Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.

Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 115.8% in Ayala Pharmaceuticals, Inc. (AYLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Ayala Pharmaceuticals Stock (AYLA)